20240018115. ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE simplified abstract (Petra Pharma Corporation)

ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE

Organization Name

Petra Pharma Corporation

Inventor(s)

Sean Douglas Aronow of Boulder CO (US)

Carina Ivonne Jette of Pasadena CA (US)

Gabrielle R. Kolakowski of Durango CO (US)

Christopher Glenn Mayne of Boulder CO (US)

Hua-Yu Wang of Chula Vista CA (US)

Michael Brian Welch of Westminster CO (US)

Nathan Edward Wright of San Diego CA (US)

Gerit Maria Pototschnig of San Diego CA (US)

Warren Christopher Chan of San Diego CA (US)

Surendra Dawadi of Longmont CO (US)

Manoj Kumar of Broomfield CO (US)

Katelyn Frances Long of Lafayette CO (US)

Alfredo Picado of Superior CO (US)

Marcos Adrian Sainz of San Diego CA (US)

Tarek Sammakia of Boulder CO (US)

LaToya Denise Scaggs of Broomfield CO (US)

Zhicheng Sun of Thornton CO (US)

Erin Danielle Anderson of Arvada CO (US)

Shuai Chen of San Diego CA (US)

Thomas Combs Irvin of Erie CO (US)

Edward A. Kesicki of New York NY (US)

Xia Wang of San Diego CA (US)

Ganesh Mangalsing Murhade of Superior CO (US)

ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE - A simplified explanation of the abstract

This abstract first appeared for US patent application 20240018115 titled 'ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE

Simplified Explanation

The abstract of the patent application describes a group of compounds and their pharmaceutically acceptable salts, along with methods of making and using these compounds. The abstract does not provide specific details about the compounds or their applications.

• The patent application relates to compounds of formula (i) and their pharmaceutically acceptable salts.
• The compounds are not defined in the abstract.
• The disclosure includes methods of making and using the compounds.
• The abstract does not provide any information about the specific methods.
• The compounds and their salts have potential applications in the field of pharmaceuticals.
• The abstract does not mention any specific applications.
• The technology solves problems related to the development of new pharmaceutical compounds.
• The abstract does not provide details about the specific problems.
• The benefits of this technology include the potential for developing new drugs or treatments.
• The abstract does not provide any specific benefits.

Potential Applications

• The compounds and their pharmaceutically acceptable salts may have applications in the development of new drugs or treatments.

Problems Solved

• The technology addresses the need for new pharmaceutical compounds.

Benefits

• The technology has the potential to lead to the development of new drugs or treatments.

Original Abstract Submitted

or pharmaceutically acceptable salts thereof wherein r, r, r, r, r, r, r, r, and r, are as defined herein. the disclosure also relates to methods of making and using compounds of formula (i) or pharmaceutically acceptable salts thereof.